Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial

Trial Profile

Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Endostatin (Primary) ; H-101 (Primary) ; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2016 Planned initiation date changed from 1 Jan 2016 to 1 Oct 2016.
    • 21 Oct 2015 New trial record
    • 19 Oct 2015 According to ClinicalTrials.gov record, the treatment table has been amended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top